CheckMate901 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)
Erstlinie
ABACUS Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder (Aktiv)
MK-3475-905 Randomisierte Phase-3-Studie zur Bewertung der Zystektomie mit perioperativer Pembrolizumab und Zystektomie mit perioperativem Enfortumab Vedotin und Pembrolizumab versus Zystektomie allein bei Cisplatin-ineligiblen Teilnehmern mit muskelinvasiver Blase Krebs (KEYNOTE-905/EV-303) (Aktiv)
VOLGA A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) (Aktiv)
Zweitlinie oder später
42756493BLC1003 Phase-1-Prüfung zum intravesikalen Erdafitinib-Verabreichungssystem (TAR-210) bei Patienten mit nicht-muskelinvasivem oder muskelinvasivem Blasenkrebs und ausgewählten FGFR-Mutationen oder -Fusionen (Aktiv)
AArau-Studie A Phase IIB study of the tetramodal therapy of T2-T4 Nx MO bladder cancer with hyperthermia combined with chemoradiotherapy following TUR-BT (Aktiv)
BAY 17403 This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CheckMate901 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
TITAN TCC TITAN-TCC (0416-ASG) is a Phase 2, open-label study of nivolumab (BMS-936558) monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and platinum-based pretreated, 2nd and 3rd line, advanced or metastatic transitional cell carcinoma subjects. Nivolumab is a fully human PD-1 antibody which blocks the respective immune checkpoint in a ligand (PD-L1/PD-L2) independent manner. (Aktiv)